Indications, complications, and outcomes following surgical management of locally advanced and metastatic renal cell carcinoma.

Abstract:

INTRODUCTION:Surgery may set the basis for a potential cure or would provide the best achievable quality of life in locally advanced or metastatic renal cell carcinoma (mRCC). However, survival extension with this approach would be scarce and not exempt from adverse events, thus preventing its recommendation in an already frail patient. An evidence based analysis on the role of surgery in each of the possible clinical scenarios involved under this heading may provide a clear picture on this issue and would be of value in the decision making process. Areas covered: Current literature was queried in PubMed/Medline in a systematic fashion. Manuscripts included were selected according to the quality of the data provided. A narrative review strategy was adopted to summarize the evidence acquired. Expert commentary: A surgery-based multimodal treatment approach should be strongly considered after adequate counseling in locally advanced and mRCC, since it may provide for additional benefits in terms of survival. However, a critical reevaluation of its adequacy, optimal timing, and selection of ideal candidates is currently ongoing.

authors

González J,Gaynor JJ,Alameddine M,Esteban M,Ciancio G

doi

10.1080/14737140.2018.1431530

subject

Has Abstract

pub_date

2018-03-01 00:00:00

pages

237-250

issue

3

eissn

1473-7140

issn

1744-8328

journal_volume

18

pub_type

杂志文章,评审
  • Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.

    abstract:INTRODUCTION:Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1247699

    authors: Weinberger V,Bednarikova M,Cibula D,Zikan M

    更新日期:2016-12-01 00:00:00

  • Benefits of laparoscopic prostate-sparing radical cystectomy.

    abstract:PURPOSE:Prostate-sparing radical cystectomy has been described in the literature and has proven to be a promising procedure owing to the continence and erectile function results without necessarily compromising the oncologic outcome in selected patients. TECHNIQUE POINTS:A transperitoneal approach is used. Lymph node ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.1.21

    authors: Rozet F,Harmon J,Arroyo C,Cathelineau X,Barret E,Vallancien G

    更新日期:2006-01-01 00:00:00

  • From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.

    abstract::One of the most prominent pathways explored in the area of targeted therapy is the PI3K/Akt/mTOR pathway, which plays a central role in cell survival and proliferation. Deregulation of this pathway has been implicated in the promotion of cancer cell growth and survival. Inhibition of several steps of this pathway has ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.1.131

    authors: Georgakis GV,Younes A

    更新日期:2006-01-01 00:00:00

  • Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era.

    abstract::Lymph node dissection in bladder cancer is an integral part of radical cystectomy. It allows for accurate staging of the patient and will, therefore, serve to dictate additional treatment and add prognostic information. The issue of what is an adequate lymphadenectomy as to the extent and boundaries of the operation, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.147

    authors: Ghavamian R,Hakimi AA

    更新日期:2009-12-01 00:00:00

  • Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery?

    abstract::Protein kinase (PK)Calpha and epsilon are rational targets for cancer therapy. However, targeted experimental therapeutics that inhibit PKCalpha or epsilon are unavailable. The authors established recently that covalent modification of an active-site cysteine in human PKCepsilon, Cys452, by small molecules, for exampl...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.2.175

    authors: O'Brian CA,Chu F,Bornmann WG,Maxwell DS

    更新日期:2006-02-01 00:00:00

  • Clinical management of borderline ovarian tumors.

    abstract::Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.90

    authors: Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

    更新日期:2010-07-01 00:00:00

  • Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

    abstract::Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.5.785

    authors: Lekakis L,de Lima M

    更新日期:2008-05-01 00:00:00

  • Role of chemotherapy in the management of soft tissue sarcomas.

    abstract::Soft tissue sarcomas are a diverse group of rare tumors that comprise 1% of all cancers. Few randomized trials of chemotherapy have been performed but there is a clear role for agents such as doxorubicin and ifosfamide in the palliation of advanced disease. There is uncertainty as to whether sequential single-agent tr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.176

    authors: Krikelis D,Judson I

    更新日期:2010-02-01 00:00:00

  • Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.

    abstract::For many decades, the use of chemotherapy as second-line therapy in non-small-cell lung cancer relied upon disease progression. Several studies have shown that four to six cycles of chemotherapy administered as front-line therapy treatment offers a survival advantage to patients; however, further chemotherapy beyond t...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.30

    authors: Velez M,Belalcazar A,Domingo G,Blaya M,Raez LE,Santos ES

    更新日期:2010-04-01 00:00:00

  • The role of stereotactic body radiotherapy and stereotactic radiosurgery in the re-irradiation of metastatic spinal tumors.

    abstract::Stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) are advanced radiotherapy delivery techniques that allow for the delivery of high-dose per fraction radiation. Advances in imaging technology and intensity modulation have allowed SRS and SBRT to be used for the treatment of tumors in close prox...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.940326

    authors: Jain AK,Yamada YJ

    更新日期:2014-10-01 00:00:00

  • Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.

    abstract::Tumors of the CNS frequently have devastating consequences in terms of cognitive and motor function, personality and mortality. Despite decades of work, current therapies have done little to alter the course of these deadly diseases. The discovery that chaperones/heat-shock proteins play an important role in tumor bio...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.5.679

    authors: Graner MW,Bigner DD

    更新日期:2006-05-01 00:00:00

  • Immunotherapy options in metastatic renal cell cancer: where we are and where we are going.

    abstract::The treatment of renal cell carcinoma is rapidly changing as a result of recent evidence concerning the efficacy of biological drugs, antiangiogenetic agents and signal-transduction inhibitors. This paper will provide a critical overview of the use of immunotherapy in renal cell carcinoma and review the available data...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.10.1459

    authors: Passalacqua R,Buti S,Tomasello G,Longarini R,Brighenti M,Dalla Chiesa M

    更新日期:2006-10-01 00:00:00

  • On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'?

    abstract:INTRODUCTION:The treatment of chronic myeloid leukemia (CML) has been drastically changed by the approval of tyrosine kinase inhibitors (TKIs). CML is now managed as a chronic disease requiring both long-term treatment and close molecular monitoring in the majority of patients. AREAS COVERED:Evidence suggests that in ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1829483

    authors: Stagno F,Breccia M,Di Raimondo F

    更新日期:2020-12-01 00:00:00

  • Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.

    abstract:INTRODUCTION:Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until in...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1785289

    authors: Manceau C,Mourey L,Pouessel D,Ploussard G

    更新日期:2020-08-01 00:00:00

  • Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.

    abstract::More than 13,000 patients died from invasive bladder cancer in 2005 alone. Radical cystectomy is the most commonly prescribed treatment for patients with muscle-invasive bladder cancer, or for those with a nonmuscle-invasive disease that is refractory to intravesical therapy. Despite advances in surgical technique and...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.2.281

    authors: Amiel GE,Lerner SP

    更新日期:2006-02-01 00:00:00

  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

    abstract::Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable. In addition, the PST setting provides an opportunity to monitor response including histopathological and biomarker examination of the tumor and host tissues before and af...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.62

    authors: Khasraw M,Bell R

    更新日期:2012-08-01 00:00:00

  • Treatment of childhood acute myeloid leukemia.

    abstract::Childhood acute myeloid leukemia is rare, but accounts for a significant number of malignancy-related deaths in this age group. However, the prognosis has improved over past decades, and survival rates of 60% and above have been reported. Still, this implies that more than a third of children and adolescents die from ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.5.917

    authors: ter Bals E,Kaspers GJ

    更新日期:2005-10-01 00:00:00

  • Surgical management of bladder cancer in 2003.

    abstract::Recent advances in molecular and cell biology have led to a greater understanding of the basic biology of bladder cancer. However, despite these advances, surgery remains a key component of modern bladder cancer treatment. Endoscopy is the mainstay of the diagnosis and treatment of superficial bladder cancer. Adjuvant...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.6.781

    authors: Wade M,Seigne JD

    更新日期:2003-12-01 00:00:00

  • Management of Merkel cell carcinoma.

    abstract::Merkel cell carcinoma is an uncommon cutaneous malignancy. Although it is rare, Merkel cell carcinoma has been described as the most malignant primary skin tumor. It is therefore important that once diagnosed, Merkel cell carcinoma is treated appropriately. The aim of this short review is to provide a summary of the a...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.1.3.441

    authors: Plunkett TA,Subrumanian R,Leslie MD,Harper PG

    更新日期:2001-10-01 00:00:00

  • Promising novel therapies for relapsed and refractory testicular germ cell tumors.

    abstract:INTRODUCTION:Germ cell tumors (GCTs) are the most common solid malignancies in young men. The overall cure rate of GCT patients in metastatic stage is excellent, however; patients with relapsed or refractory disease have poor prognosis. Attempts to treat refractory disease with novel effective treatment to improve prog...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1838279

    authors: Kozakova K,Mego M,Cheng L,Chovanec M

    更新日期:2020-11-02 00:00:00

  • Therapeutic endoscopy and endoscopic ultrasound for gastrointestinal malignancies.

    abstract::Gastrointestinal endoscopy and endoscopic ultrasound not only provide strategies to diagnose and stage malignancy, but also to administer palliative and definitive care. Options for anticancer therapy include endoscopic mucosal resection, photodynamic therapy, thermal therapy, self-expanding metal stents and recently,...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.4.705

    authors: Wong RF,Bhutani MS

    更新日期:2005-08-01 00:00:00

  • RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.

    abstract::Cancer immunotherapy aims at eliciting an immune response directed against tumor antigens to help fight off residual tumor cells and, thereby, improve the survival and quality of life of cancer patients. Different immunotherapeutic approaches share the use of dendritic cells (DCs) to present tumor-associated antigens ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,收录出版,评审

    doi:10.1586/14737140.9.1.97

    authors: Tyagi RK,Mangal S,Garg N,Sharma PK

    更新日期:2009-01-01 00:00:00

  • New treatment strategies for malignant gliomas.

    abstract::Malignant gliomas are the most prevalent type of primary brain tumor in adults. Despite progress in brain tumor therapy, the prognosis of malignant glioma patients remains dismal. The median survival of patients with glioblastoma multiforme, the most common grade of malignant glioma, is 10-12 months. Conventional ther...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.7.1087

    authors: Sathornsumetee S,Rich JN

    更新日期:2006-07-01 00:00:00

  • TIM-3 pathway dysregulation and targeting in cancer.

    abstract:INTRODUCTION:Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer. Promising activity with immunotherapy has been reported in numerous malignancie...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1865814

    authors: Zeidan AM,Komrokji RS,Brunner AM

    更新日期:2021-01-19 00:00:00

  • Pioneering the trail of cancer immunotherapy.

    abstract::The annual conference of the International Society for Biological Therapy of Cancer (iSBTc), recently renamed the Society for Immunotherapy of Cancer (SITC), provides clinicians and scientists with a uniquely broad yet focused view of the growing field of tumor immunology and cancer immunotherapy. In this time of exci...

    journal_title:Expert review of anticancer therapy

    pub_type:

    doi:10.1586/era.10.229

    authors: Kotlan B,Balwit JM

    更新日期:2011-03-01 00:00:00

  • Is axillary dissection needed in node-positive breast cancer?

    abstract::The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axil...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.8.2.195

    authors: Greenberg CC,Bafford AC,Golshan M

    更新日期:2008-02-01 00:00:00

  • New drug therapies for advanced renal cell carcinoma.

    abstract::The incidence of renal cell cancer is increasing and surgery is the only curative treatment for patients presenting with localized disease at diagnosis. The treatment of metastatic renal cell cancer is palliative and, until recently, immunotherapy has been the standard treatment approach with response rates between 10...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.1.57

    authors: Gore ME,Harrison ML,Montes A

    更新日期:2007-01-01 00:00:00

  • Transsphenoidal microsurgery: past, present and future.

    abstract::In this report, we first describe the history of transsphenoidal surgery. We further elaborate on three fundamental surgical anatomy principles of transsphenoidal surgery for pituitary adenomas. First, the pituitary gland and, therefore, pituitary adenomas are extra-arachnoid structures, therefore the operation should...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.9s.S75

    authors: Ciric IS,Zhao J

    更新日期:2006-09-01 00:00:00

  • Raloxifene for the treatment and prevention of breast cancer?

    abstract::Raloxifene is a member of a family of drugs known as selective estrogen receptor modulators (SERMs). Raloxifene is currently approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. SERMs hold the potential to treat and prevent breast cancer, osteoporosis and coronary heart disease...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.1.3.334

    authors: Pappas SG,Jordan VC

    更新日期:2001-10-01 00:00:00

  • Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.

    abstract:INTRODUCTION:Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1770088

    authors: Feld J,Belasen A,Navada SC

    更新日期:2020-06-01 00:00:00